Fate Therapeutics shares are trading higher after the company announced FDA clearance of its Investigational New Drug application for its CAR T-cell product candidate FT839.

Benzinga Newsdesk www.benzinga.com Positive 94.8%

Neg 0% Neu 0% Pos 94.8%

Comments

No comments yet. Be the first!